|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
|
|
|
|
Exhibit Number
|
|
Exhibit Title or Description
|
|
|
|
|
Press Release, dated November 13, 2023
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
GYRE THERAPEUTICS, INC.
|
|
|
|
|
Date: November 13, 2023
|
By:
|
/s/ Charles C. Wu, Ph.D.
|
|
Name:
|
Charles C. Wu, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
• |
Hydronidone significantly improved liver damage in carbon tetrachloride
(CCL4) and 3,5-diethoxycarbonyl-1,4-dihydropyridine (DDC) mouse hepatic fibrosis models and reduced the accumulation of collagen
|
•
|
Hydronidone inhibited the activation of hepatic stellate cells via Smad7-mediated TGF-β degradation and decreased the expression of fibrosis genes in hepatic stellate cells
|
•
|
In a ubiquitin-proteasome dependent pathway, Hydronidone promoted the Caveolin-1 mediated TGFβRI degradation via Smad7
|
•
|
Specific knockdown of Smad7 in vivo blocked the antifibrosis effect of Hydronidone
|
X5E6H8>I[T9),VI5:T-)1;1]&T5Y
M]X_L !T]Z\N\0>*]1\02
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MB7%PK6]AG)
Document and Entity Information |
Nov. 13, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 13, 2023 |
Entity File Number | 000-51173 |
Entity Registrant Name | Gyre Therapeutics, Inc. |
Entity Central Index Key | 0001124105 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2020050 |
Entity Address, Address Line One | 12770 High Bluff Drive |
Entity Address, Address Line Two | Suite 150 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | 619 |
Local Phone Number | 949-3681 |
Title of 12(b) Security | Common Stock |
Trading Symbol | GYRE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
C@!HNIP;W?19%%2%'^24R
M<%AS79Y.^:_$KX\-P+S=2(PX S+&H& .U*_]]MR45L_P. %6''=ABAF-3Q/&
M1[_Q\;'4-]E6F1J6_*!MFMEJ)6OW0I53VN=K+^)AA^CP3/B!J/
M+U6*W=/?YO?G;N.#^M%\[T.@5LKJ;V!Y9/D1 ,\!3DHS#,VPZG;3LLDTV8JJ
M=4G]O1ZD/4>'FF@3*K5G1+(-\JQ !F$WJX4X2#,HK628E-^T(,WS= ! ,AP1
MF<:"D2 &K)B4Y^EPE]AW"_L<85+!SV@*-A6BW ,V